Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?

Human epidermal receptor type 2 (HER2; also known as ErbB2) is an idea target for target therapy. HER2-targeted treatments with trastuzumab and its derivates or analogues can improve the overall survival of patients with HER2-overexpression tumors. This chapter describes the construction and clinical translational study of 64Cu-NOTA-Trastuzumab, 124I-Trastuzumab, and 68Ga-HER2 affibody tracer. Inspired by recently most popular peptide receptor radionuclide therapy with lutetium-177 dotatate (177Lu-DOTATATE) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and 177Lu-PSMA-617 for metastatic castration resistant prostate cancer therapy (mCRPC), the establishment of affibody receptor radionuclide therapy (ARRT) has the potential to provide an alternative treatment option for future HER2 positive resistant patients.